NVO - Novo Nordisk A/S
After hours:
| Previous close | 159.81 |
| Open | 159.92 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's range | 159.26 - 161.11 |
| 52-week range | 95.02 - 172.97 |
| Volume | |
| Avg. volume | 1,435,850 |
| Market cap | 361.298B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 41.36 |
| EPS (TTM) | 3.88 |
| Earnings date | N/A |
| Forward dividend & yield | 1.76 (1.10%) |
| Ex-dividend date | 24 Mar 2023 |
| 1y target est | 170.01 |
ZacksPfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
Motley FoolGot $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors.
Motley FoolDoes Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
Motley FoolThis Could Be Novo Nordisk's Next Big Weight-Loss Product
The company's sales doubled last quarter, prompting it to upgrade its guidance.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Motley FoolThe Best Stocks to Invest $5,000 in Right Now
Two that come to mind are Danish pharmaceutical company Novo Nordisk (NYSE: NVO) and U.S.-based integrated healthcare benefits company UnitedHealth Group (NYSE: UNH). The companies have their own tailwinds as well, with Novo Nordisk building revenue off its weight-loss franchise and UnitedHealth Group finding its foray into Medicare Advantage to be lucrative. Novo Nordisk's shares are up more than 19%.
ZacksBrokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Motley FoolBetter Dividend Stock: Eli Lilly or Novo Nordisk?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
Globe NewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 30 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiate
Motley FoolThis Pharma's Sales Are So Hot It's Trying to Curb Demand
Novo Nordisk (NYSE: NVO) is planning to pause some of its advertising campaigns for its obesity drug Wegovy, due to white-hot demand in the U.S. The impact of the move isn't the marketing costs it saves, but the unambiguous message it sends: Wegovy is probably going to bring in even more sales than management expected -- and it had expected quite a bit. This isn't the first time that demand for Wegovy has been greater than what the pharma can manufacture, and it's no surprise why.
ZacksNovo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Yahoo Finance VideoPfizer weight loss drug may be as effective as competitors: Study
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
ZacksHere's Why Novo Nordisk (NVO) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Globe Newswire
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) receives CHMP positive opinion for expanded use in children and adolescents with growth hormone deficiency
Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya® (somapacitan) for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. Symptoms of growth hormone deficiency in children often start early in life, leading to short stature
ZacksTime to Buy Stock in These Pharmaceutical Giants for EPS Growth
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
ZacksNovo Nordisk (NVO) Collaborates for Gene-Editing Therapies
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
ZacksIs Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
- Globe Newswire
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk
Motley FoolWhy Novo Nordisk Stock Is Falling Today
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.
ZacksNovo Nordisk (NVO) Announces Positive Obesity Program Data
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
ZacksBristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
ZacksPfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Yahoo Finance VideoPfizer stock rises on positive results from weight loss drug study
Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.
- Zacks
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
